Research Article

Homocysteine Level and Risk of Hemorrhage in Brain Arteriovenous Malformations

Chaofan Zeng,1,2,3,4 Fa Lin,1,2,3,4 Peicong Ge,1,2,3,4 Dong Zhang,1,2,3,4 Shuo Wang,1,2,3,4 and Jizong Zhao1,2,3,4,5

1Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No. 119 South Fourth Ring Rd West, Fengtai District, Beijing 100070, China
2China National Clinical Research Center for Neurological Diseases, Beijing 100070, China
3Center of Stroke, Beijing Institute for Brain Disorders, Beijing 100070, China
4Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing 100070, China
5Savaid Medical School, University of the Chinese Academy of Sciences, Beijing, China

Correspondence should be addressed to Jizong Zhao; zhaojz205@163.com

Received 18 August 2020; Revised 10 September 2020; Accepted 20 March 2021; Published 31 March 2021

Academic Editor: Wen-Jun Tu

Copyright © 2021 Chaofan Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. We aimed to investigate the risk factors associated with hemorrhage and clarify the relation of homocysteine (Hcy) with brain arteriovenous malformations (bAVMs).

Method. We retrospectively reviewed bAVM patients from Beijing Tiantan Hospital between January 2019 and December 2019. Clinical and laboratory variables were analyzed in enrolled patients with bAVMs. Potential predictors associated with hemorrhage were evaluated by logistic regression analysis. Results. A total of 143 bAVM patients were identified in the study, including 69 unruptured and 74 ruptured cases. Patients with hemorrhage were less likely to have hyperhomocysteinemia ($P=0.023$). Logistic regression analysis showed that increased maximum diameter of bAVM lesions (odds ratio (OR) 0.634, 95% confidence intervals (CI) 0.479-0.839; $P=0.001$) and serum Hcy level (OR 0.956, 95% CI 0.920-0.993; $P=0.021$) were associated with lower risk of hemorrhage in bAVMs. Conclusion. The present study provided evidence regarding the association between serum Hcy and hemorrhage in patients with bAVMs. Higher Hcy level was correlated with a lower risk of rupture. Detection of factors for subsequent hemorrhage is necessary to develop therapeutic strategies for bAVMs preferably.

1. Introduction

Brain arteriovenous malformations (bAVMs) are congenital collection of dilated arteries and draining veins without capillary beds, forming high-flow arterial blood shunts directly into the venous system [1, 2]. Intracranial hemorrhage manifests as the most common onset symptom with an annual rupture rate ranged from 2%-4%, which results in a high incidence of neurological morbidity and mortality [3, 4]. Although our understanding of bAVMs has progressed in recent years, causal relationships and the mechanisms by which bAVMs initiation, progression, and rupture remain poorly elusive.

Homocysteine (Hcy) is a nonessential amino acid from the methionine and folate cycle, a metabolic product critical for numerous biochemical processes. Clinically, normal serum level ranges from 5-10 μmol/L, and incremental elevation above 15 μmol/L is termed as hyperhomocysteinemia (HHcy) [5]. Previous studies and analyses suggested the atherogenic, thrombogenic, and procoagulant effects of Hcy [6, 7], which overlap the acknowledged pathogenic mechanism of bAVMs [8]. The major mechanisms were summarized as intracranial vascular injuries [9, 10], vascular wall remodeling [11, 12], hemodynamic stress [11], and diameter and hematoma expansion [13, 14]. Elevated serum Hcy is emerging as an independent risk factor for slow-flow occlusive
cardiovascular diseases, neurodegenerative diseases, and ischemic stroke [6, 15]. However, after McEvoy et al. first presented the relationship between Hcy and hemorrhagic stroke [16], its role in hemorrhagic stroke subsequently reported remains controversial [17–19], let alone in bAVMs. Currently, most studies, including meta-analyses, failed to confirm this association [20–22].

To the best of our knowledge, no clinical study with relevant evidence that correlates Hcy with bAVMs has been performed so far. Thus, in the present study, we conducted this untargeted analysis to explore the risk factors associated with initial rupture and to clarify the relation of Hcy with bAVMs.

2. Materials and Methods

2.1. Study Design and Participants. We retrospectively reviewed patients diagnosed with bAVMs at the Department of Neurosurgery, Beijing Tiantan Hospital from January 2019 to December 2019. This study was approved by the Institutional Review Board of our institution. Informed consent was waived considering the retrospective design of the study.

Among 356 patients with cerebral vascular malformations admitted to our hospital between January 2019 and December 2019, 332 patients were diagnosed with bAVMs using magnetic resonance imaging (MRI) or digital subtraction angiography (DSA). Patients were excluded as follows: (i) with malignancies, chronic renal insufficiency, hematological diseases, or hypothyroidism; (ii) with inadequate laboratory or DSA data. Finally, 143 patients were included in the study (Figure 1).

2.2. Data Collection. Demographic data, medical and operative history, clinical manifestations, bAVM characteristics, and laboratory results were obtained. Medical history including hypertension, diabetes mellitus, hyperlipidemia, cigarette smoking, and alcohol drinking were obtained. The history of prior treatment included endovascular embolization, radiosurgery, and microsurgery. Initial manifestations were summarized into three categories: hemorrhage, seizure, and neurological dysfunction. BAVM characteristics included size of lesion, eloquent and deep location, venous drainage, and associated aneurysms. The AVM volume was calculated by \( \frac{a \times b \times c}{2} \) [23], and the Spetzler-Martin (SM) grading scale was evaluated to classify the bAVMs. Two experienced investigators (C.Z. and F.L.) independently reviewed the MRI and DSA images. Neurological status was assessed using the modified Rankin Scale (mRS) score at admission.

Heart rate and blood pressure were also recorded. Body mass index (BMI) was calculated as weight (kg)/[height (m)]². Besides, fast venous blood samples were collected in the morning after admission for all patients. Levels of blood glucose, albumin (ALB), creatinine, uric acid (UA), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A (ApoA), apolipoprotein B (ApoB), and homocysteine (Hcy) were measured using enzymatic methods. Serum Hcy ≥ 15.0 μmol/L was considered as HHcy.

2.3. Statistical Analysis. All statistical analyses were performed using SPSS (version 26.0, IBM). The categorical variables were presented as frequencies, and continuous variables were described with mean (standard deviation, SD) or median (interquartile range, IQR). The chi-square test or Fisher exact test was conducted to compare categorical variables between groups. Continuous variables were compared using the two-tailed Student’s t test or Mann–Whitney U test. The association between characteristics and Hcy quartiles was assessed using the Cochran-Armitage test for bivariate variables and Spearman’s rank correlation test for continuous variables. Logistic regression analysis was performed to identify the risk factors for hemorrhage of bAVMs. Odds ratios (ORs) were calculated with 95% confidence intervals (CIs). Further exploration of Hcy associated with hemorrhage was conducted by adjusted models. \( P \) value < 0.05 indicated statistical significance.

3. Results

3.1. Clinical and Laboratory Characteristics of bAVM Patients. Baseline characteristics according to the hemorrhagic manifestation were shown in Table 1. A total of 143 patients with bAVMs were enrolled in the study. Compared with unruptured participants, patients with ruptured bAVMs tended to exhibit poor neurological status (mRS > 2) and less likely presented with seizure \( (P < 0.001 \text{ for both}) \). Although the SM grade was found no difference between groups \( (P = 0.149) \), the average size of bAVMs was smaller in ruptured patients than in those without hemorrhage \( (P < 0.001 ) \). In addition, ruptured bAVMs showed lower levels of UA \( (P = 0.032) \). HHcy was found in 28 (40.6%) unruptured patients and 17 (23.9%) ruptured patients \( (P = 0.023) \).

3.2. Clinical Characteristics of bAVM Patients according to Hcy Quartiles. Analysis of the clinical characteristics according to Hcy quartiles was summarized in Table 2. A
Table 1: Baseline characteristics of bAVM patients.

| Variables                        | Total (n = 143) | Unruptured (n = 69) | Ruptured (n = 74) | P value |
|----------------------------------|----------------|---------------------|------------------|---------|
| Age, y, mean (SD)                | 29.6 (14.0)    | 31.0 (13.1)         | 28.2 (14.6)      | 0.221   |
| Sex, male (%)                    | 79 (55.2)      | 37 (53.6)           | 42 (56.8)        | 0.706   |
| Medical history (%)              |                |                     |                  |         |
| Hypertension (%)                 | 9 (6.3)        | 2 (2.9)             | 7 (9.5)          | 0.204   |
| Diabetes mellitus (%)            | 3 (2.1)        | 1 (1.4)             | 2 (2.7)          | 1.000   |
| Hyperlipidemia (%)               | 1 (0.7)        | 0 (0)               | 1 (1.4)          | 1.000   |
| Cigarette smoking (%)            | 26 (18.2)      | 12 (17.4)           | 14 (18.9)        | 0.813   |
| Alcohol drinking (%)             | 16 (11.2)      | 7 (10.1)            | 9 (12.2)         | 0.702   |
| Prior treatments (%)             |                |                     |                  |         |
| Embolization (%)                 | 21 (14.7)      | 7 (10.1)            | 14 (18.9)        | 0.139   |
| Radiosurgery (%)                 | 6 (4.2)        | 1 (1.4)             | 5 (6.8)          | 0.244   |
| Microsurgery (%)                 | 5 (3.5)        | 2 (2.9)             | 3 (4.1)          | 1.000   |
| Primary symptom (%)              |                |                     |                  |         |
| Hemorrhage (%)                   | 74 (51.7)      | 0 (0)               | 74 (100.0)       | <0.001* |
| Seizure (%)                      | 30 (21.0)      | 25 (36.2)           | 5 (6.8)          | <0.001* |
| Neurological dysfunction (%)     | 29 (20.3)      | 15 (21.7)           | 14 (18.9)        | 0.675   |
| Admission mRS > 2 (%)            | 15 (10.5)      | 1 (1.4)             | 14 (18.9)        | <0.001* |
| AVM characteristics               |                |                     |                  |         |
| Spetzler-Martin grade (%)        |                |                     |                  | 0.149   |
| I-II                             | 81 (56.6)      | 34 (49.3)           | 47 (63.5)        |         |
| III                              | 42 (29.4)      | 22 (31.9)           | 20 (27.0)        |         |
| IV-V                             | 20 (14.0)      | 13 (18.8)           | 7 (9.5)          |         |
| Maximum diameter, cm, median (IQR) | 3.4 (2.5-4.6) | 3.9 (3.0-5.1)      | 2.9 (2.3-4.1)   | <0.001* |
| Volume, cm³, median (IQR)        | 8.6 (4.4-25.0) | 15.8 (6.2-33.7)    | 6.0 (3.5-15.3)  | <0.001* |
| Deep location (%)                | 33 (23.1)      | 16 (23.2)           | 17 (23.0)        | 0.976   |
| Eloquent location (%)            | 72 (50.3)      | 34 (49.3)           | 38 (51.4)        | 0.804   |
| Deep venous drainage (%)         | 43 (30.1)      | 21 (30.4)           | 22 (29.7)        | 0.927   |
| Associated aneurysms (%)         | 21 (14.7)      | 10 (14.5)           | 11 (14.9)        | 0.950   |
| Clinical features, mean (SD)     |                |                     |                  |         |
| Heart rate, bpm                  | 80 (10)        | 80 (9)              | 81 (11)          | 0.405   |
| SBP, mm Hg                       | 120 (15)       | 120 (13)            | 120 (17)         | 1.000   |
| DBP, mm Hg                       | 77 (10)        | 76 (10)             | 78 (11)          | 0.434   |
| BMI, kg/m²                       | 22.6 (4.4)     | 23.2 (4.4)          | 22.0 (4.4)       | 0.099   |
| Laboratory results, median (IQR) |                |                     |                  |         |
| Glucose, mmol/L                  | 4.6 (4.3-5.0)  | 4.6 (4.3-4.8)       | 4.6 (4.4-5.1)    | 0.141   |
| Albumin, g/L                     | 43.9 (41.3-46.0)| 44.4 (41.6-46.1)  | 43.5 (41.0-45.9) | 0.511   |
| Creatinine, μmol/L               | 58.6 (46.6-68.5)| 59.5 (49.7-70.9) | 56.2 (45.2-67.8) | 0.109   |
| UA, μmol/L                       | 314.0 (257.7-366.5)| 324.5 (280.8-374.8)| 294.0 (241.8-357.1)| 0.032* |
| TC, mmol/L                       | 4.3 (3.6-4.8)  | 4.3 (3.8-4.9)       | 4.2 (3.5-4.8)    | 0.468   |
| TG, mmol/L                       | 1.0 (0.7-1.5)  | 1.1 (0.8-1.6)       | 0.9 (0.7-1.5)    | 0.130   |
| HDL-C, mmol/L                    | 1.2 (1.0-1.5)  | 1.2 (1.0-1.4)       | 1.2 (1.1-1.5)    | 0.701   |
| LDL-C, mmol/L                    | 2.6 (2.0-3.2)  | 2.8 (2.1-3.5)       | 2.5 (1.9-3.1)    | 0.080   |
| ApoA, g/L                        | 1.3 (1.1-1.4)  | 1.3 (1.1-1.4)       | 1.3 (1.1-1.4)    | 0.588   |
| ApoB, g/L                        | 0.8 (0.7-1.0)  | 0.9 (0.7-1.1)       | 0.8 (0.7-0.9)    | 0.211   |
| Hcy, μmol/L                      | 12.4 (9.9-16.2)| 13.3 (10.4-18.9)   | 11.7 (9.7-14.6)  | 0.057   |
| HHcy (%)                         | 45 (31.5)      | 28 (40.6)           | 17 (23.0)        | 0.023*  |

bAVM: brain arteriovenous malformation; SD: standard deviation; mRS: modified Rankin Scale; IQR: interquartile range; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; UA: uric acid; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA: apolipoprotein A; ApoB: apolipoprotein B; Hcy: homocysteine; HHcy: hyperhomocysteinemia. *P < 0.05, significant difference.
relationship was observed between Hcy level and male sex ($P < 0.001$). Serum Hcy level was also correlated with age ($P = 0.005$) and cigarette smoking ($P = 0.007$). Furthermore, Hcy was related to seizure manifestation and poor neurological status ($P < 0.05$ for all). Although the incidence of hemorrhage was no significant difference between Hcy quartiles ($P = 0.093$), a relatively lower risk of rupture occurred in the groups of higher Hcy concentration (Q1: 58.3%; Q2: 57.1%; Q3: 52.8%; Q4: 38.9%). The SM grade and other variables were similar across Hcy quartiles ($P > 0.05$ for all).

### 3.3. Analysis of Predictors for Hemorrhage of bAVMs

Predictors for the hemorrhagic presence of bAVMs were analyzed (Table 3). Univariate analysis showed that the maximum diameter of bAVM lesions and level of serum Hcy were associated with hemorrhage. After incorporating the covariates of age, male sex, smoking, prior embolization, deep location, eloquent location, deep venous drainage, and associated aneurysms into the multivariate analysis, maximum diameter of bAVM lesions and level of serum Hcy were associated with hemorrhage (OR 0.956, 95% CI 0.920-0.993; $P = 0.021$) were shown to be significantly related to hemorrhage.

Prior to adjusting for potential covariables (Figure 2), HHcy was associated with the hemorrhagic presence (OR 0.437, 95% CI 0.212-0.901; $P = 0.025$). After adjusting for age, male sex, smoking, prior embolization, deep location, eloquent location, deep venous drainage, and associated aneurysms, HHcy was correlated with a lower risk of hemorrhage (OR 0.381, 95% CI 0.165-0.881; $P = 0.024$). The curve of regression model was fitted to reveal the linear relationship between Hcy level and probability of hemorrhage (Figure 3).

### 4. Discussion

In this retrospective study, we identified the potential risk factors for hemorrhage of bAVMs and investigated the association between serum Hcy level and bAVMs’ rupture. HHcy was observed significantly less in patients with the hemorrhagic presentation. Furthermore, we found that increased size of bAVM lesions and higher levels of Hcy were correlated with a lower risk of hemorrhage.

Although HHcy was proved to be an independent risk factor for ischemic stroke [24], the relationship between intracranial hemorrhage and HHcy has not been extensively

---

**Table 2: Characteristics of bAVM patients according to Hcy quartiles.**

| Variables                      | All (n = 143) | Hcy quartiles, μmol/L | $P$ trend |
|--------------------------------|--------------|-----------------------|----------|
|                                | Q1 (n = 36)  | Q2 (n = 35)           | Q3 (n = 36)| Q4 (n = 36) |        |
| Age, y, mean (SD)              | 29.6 (14.0)  | 23.8 (16.0)           | 30.2 (13.7)| 35.4 (12.8)| 28.9 (10.9)| 0.005*  |
| Sex, male (%)                  | 79 (55.2)    | 11 (30.6)             | 17 (48.6) | 22 (61.1) | 29 (80.6) | <0.001* |
| Medical history (%)            |              |                       |          |          |          |         |
| Hypertension                   | 9 (6.3)      | 1 (2.8)               | 2 (5.7)  | 4 (11.1) | 2 (5.6)  | 0.448   |
| Diabetes mellitus              | 3 (2.1)      | 0 (0)                 | 1 (2.9)  | 1 (2.8)  | 1 (2.8)  | 0.438   |
| Hyperlipidemia                 | 1 (0.7)      | 0 (0)                 | 0 (0)    | 1 (2.8)  | 0 (0)    | 0.657   |
| Cigarette smoking              | 26 (18.2)    | 1 (2.8)               | 6 (17.1) | 10 (27.8)| 9 (25.0) | 0.007*  |
| Alcohol drinking               | 16 (11.2)    | 0 (0)                 | 4 (11.4) | 8 (22.2) | 4 (11.1) | 0.060   |
| Primary symptom (%)            |              |                       |          |          |          |         |
| Hemorrhage                     | 74 (51.7)    | 21 (58.3)             | 20 (57.1)| 19 (52.8)| 14 (38.9)| 0.093   |
| Seizure                        | 30 (21.0)    | 4 (11.1)              | 6 (17.1) | 9 (25.0) | 11 (30.6)| 0.029*  |
| Neurological dysfunction       | 29 (20.3)    | 8 (22.2)              | 7 (20.0) | 8 (22.2) | 6 (16.7) | 0.629   |
| Admission mRS > 2 (%)          | 15 (10.5)    | 9 (25.0)              | 1 (2.9)  | 2 (5.6)  | 3 (8.3)  | 0.037*  |
| AVM characteristics            |              |                       |          |          |          |         |
| Spetzler-Martin grade (%)      |              |                       |          |          |          | 0.660   |
| I-I                            | 81 (56.6)    | 17 (47.2)             | 23 (65.7)| 20 (55.6)| 21 (58.3)|          |
| III                           | 42 (29.4)    | 13 (36.1)             | 8 (22.9) | 12 (33.3)| 9 (25.0) |          |
| IV-V                          | 20 (14.0)    | 6 (16.7)              | 4 (11.4) | 4 (11.1) | 6 (16.7) |          |
| Maximum diameter, cm, median (IQR) | 3.4 (2.5-4.6) | 4.0 (2.6-4.7) | 3.0 (2.5-4.4) | 3.0 (2.3-3.9) | 3.7 (2.6-5.1) | 0.183 |
| Volume, cm$^3$, median (IQR)   | 8.6 (4.4-25.0) | 10.9 (5.2-29.7) | 7.2 (5.0-19.3) | 8.2 (3.2-17.7) | 13.9 (4.3-31.8) | 0.239 |
| Deep location (%)              | 33 (23.1)    | 8 (22.2)              | 7 (20.0) | 8 (22.2) | 10 (27.8)| 0.549   |
| Eloquent location (%)          | 72 (50.3)    | 19 (52.8)             | 18 (51.4)| 19 (52.8)| 16 (44.4)| 0.526   |
| Diffusive nidus (%)            | 68 (47.6)    | 21 (58.3)             | 17 (48.6)| 10 (27.8)| 20 (55.6)| 0.434   |
| Deep venous drainage (%)       | 43 (30.1)    | 12 (33.3)             | 8 (22.9) | 13 (36.1)| 10 (27.8)| 0.916   |
| Associated aneurysms (%)       | 21 (14.7)    | 6 (16.7)              | 5 (14.3) | 6 (16.7) | 4 (11.1) | 0.588   |

bAVM: brain arteriovenous malformation; Hcy: homocysteine; SD: standard deviation; mRS: modified Rankin Scale; IQR: interquartile range. * $P < 0.05$, significant difference. aSerum levels of Hcy in quartiles: Q1, ≤10.0 μmol/L; Q2, 10.0-12.3 μmol/L; Q3, 12.4-16.1 μmol/L; and Q4, >16.1 μmol/L.
studied. A previous study involving 503 patients with ICH reported that the risk of hemorrhage in patients with HHcy was 1.94-fold compared to the controls [17]. A recent meta-analysis showed that Hcy levels in patients with ICH were significantly higher than in healthy participants [19]. Various diseases are characterized by intracranial hemorrhage, including hypertension, cerebral amyloid angiopathy, intracranial aneurysms, and bAVMs. Wang et al. reported that HHcy was an independent risk factor for the formation of intracranial aneurysms in the Chinese Han population [25]. HHcy may also be associated with the rupture of intracranial aneurysms in animal experiments [12]. According to the study by Kumar et al., higher serum Hcy level was observed in SAH patients as compared to healthy controls [26]. However, other studies demonstrated the contrary results. Dhandapani et al. revealed that the increased Hcy was significantly associated with favorable outcomes following SAH [27]. Moreover, a lower concentration of Hcy was verified as the predictor for hematoma expansion of ICH in cerebral small vessel diseases [28].

In our study, Hcy was proved to be associated with rupture in bAVM patients. Surprisingly, ruptured bAVMs had less

| Variables                  | Univariate analysis | Multivariate analysis |
|----------------------------|---------------------|-----------------------|
|                            | OR                  | 95% CI                | P value | OR                  | 95% CI                | P value |
| Age                        | 0.985               | 0.962-1.009           | 0.220   | 0.980               | 0.954-1.007           | 0.154   |
| Male sex                   | 1.135               | 0.587-2.196           | 0.707   | 1.565               | 0.686-3.568           | 0.287   |
| Medical history            |                     |                       |         |                     |                       |         |
| Hypertension               | 3.500               | 0.701-17.467          | 0.127   |                     |                       |         |
| Diabetes mellitus          | 1.889               | 0.167-21.311          | 0.607   |                     |                       |         |
| Cigarette smoking          | 1.108               | 0.473-2.598           | 0.813   | 0.974               | 0.325-2.914           | 0.962   |
| Alcohol drinking           | 1.226               | 0.430-3.495           | 0.703   |                     |                       |         |
| Prior treatments           |                     |                       |         |                     |                       |         |
| Embolization               | 2.067               | 0.780-5.475           | 0.144   | 2.848               | 0.868-9.347           | 0.084   |
| Radiosurgery               | 4.928               | 0.561-43.286          | 0.150   |                     |                       |         |
| Microsurgery               | 1.415               | 0.229-8.737           | 0.708   |                     |                       |         |
| AVM characteristics        |                     |                       |         |                     |                       |         |
| Maximum diameter           | 0.668               | 0.519-0.859           | 0.002   | 0.634               | 0.479-0.839           | 0.001*  |
| Deep location              | 1.012               | 0.465-2.205           | 0.976   | 1.271               | 0.507-3.187           | 0.609   |
| Eloquent location          | 1.087               | 0.564-2.094           | 0.804   | 1.230               | 0.561-2.698           | 0.605   |
| Deep venous drainage       | 0.967               | 0.473-1.977           | 0.927   | 0.914               | 0.391-2.135           | 0.836   |
| Associated aneurysms       | 1.030               | 0.408-2.603           | 0.950   | 1.184               | 0.415-3.380           | 0.753   |
| Clinical features          |                     |                       |         |                     |                       |         |
| Heart rate                 | 1.014               | 0.981-1.049           | 0.402   |                     |                       |         |
| SBP                        | 1.000               | 0.978-1.022           | >0.999  |                     |                       |         |
| DBP                        | 1.013               | 0.981-1.046           | 0.432   |                     |                       |         |
| BMI                        | 0.937               | 0.867-1.013           | 0.102   |                     |                       |         |
| Laboratory results         |                     |                       |         |                     |                       |         |
| Glucose                    | 1.510               | 0.965-2.362           | 0.071   |                     |                       |         |
| Albumin                    | 0.976               | 0.886-1.074           | 0.614   |                     |                       |         |
| Creatinine                 | 0.978               | 0.957-1.000           | 0.051   |                     |                       |         |
| UA                         | 1.000               | 0.999-1.001           | 0.964   |                     |                       |         |
| TC                         | 0.912               | 0.638-1.305           | 0.616   |                     |                       |         |
| TG                         | 1.052               | 0.764-1.449           | 0.756   |                     |                       |         |
| HDL-C                      | 1.819               | 0.851-3.886           | 0.123   |                     |                       |         |
| LDL-C                      | 0.724               | 0.493-1.064           | 0.100   |                     |                       |         |
| ApoA                       | 0.916               | 0.272-3.089           | 0.888   |                     |                       |         |
| ApoB                       | 0.404               | 0.081-2.012           | 0.269   |                     |                       |         |
| Hcy                        | 0.965               | 0.934-0.998           | 0.038   | 0.956               | 0.920-0.993           | 0.021*  |

OR: odds ratio; CI: confidence intervals; AVM: arteriovenous malformation; SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass index; UA: uric acid; TC: total cholesterol; TG: triglyceride; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; ApoA: apolipoprotein A; ApoB: apolipoprotein B; Hcy: homocysteine. *P < 0.05, significant difference.
proportion of HHcy, and the level of Hcy was an independent protective factor for hemorrhage. Hcy is an amino acid involved in the metabolism of methionine and folate cycle. The permeability of cerebrovascular endothelial cells is increased with MMP-9 (matrix metalloproteinase-9) activated by Hcy, accompanied with blood-brain barrier (BBB) destruction [29]. It has been found that Hcy may further activate MMP-9 through extracellular signal-regulated kinase (ERK) pathway and inhibition of γ-aminobutyric acid (GABA) receptor in endothelial cells [30]. MMP-9 may also disrupt the BBB by degrading type IV collagenase, laminin, and fibronectin in extracellular matrix and basement membrane; activating vascular endothelial growth factor (VEGF) and thrombin; inducing apoptosis, which exacerbates the occurrence of ICH [31]. Furthermore, increased levels of MMP-9 were observed in bAVMs. The abnormal expression of MMP-9 destabilized the vessels, which potentially leads to the rupture of bAVM lesions [32]. Alternatively, the results may be associated with hemodynamic abnormalities. Recent studies have documented the effects of Hcy on arterial hemodynamics [33–35]. Several lines of evidence suggested a converse relationship between Hcy and flow velocity for the coronary arteries [33, 35].
The elevated level of serum Hcy was connected with the phenomenon of slow flow in coronary arteries. Oxidative stress and endothelial destruction related to Hcy were suggested to be the leading cause of slow coronary flow [33, 34]. Likewise, Hcy was shown to be associated with augmented arterial resistance in patients with internal carotid stenosis [36]. The altered hemodynamics may attribute to the remodeling of arterials with the effect of HHcy. Sun et al. reported that the flow velocity of internal carotid arteries and vertebral arteries was inversely correlated with Hcy quartiles in healthy participants, despite the parameters were not significantly different after the adjustments [37]. The difference of conclusions may be related to the inaccuracy of the data collected through carotid Doppler ultrasound, instead of transcranial Doppler sonography (TCD). As described, high-flow and low-resistance arterial blood flows directly into the venous system under the conditions of insufficient intervening capillaries in bAVMs, which carries a high risk of hemorrhage [1]. In this study, we revealed that the probability of hemorrhage was decreased in bAVM patients with higher Hcy. Therefore, we supposed that hemodynamic abnormalities induced by Hcy play an important role in the pathogenesis of bAVMs’ rupture. The present results highlighted the correlation between Hcy and hemorrhage in bAVMs.

Specific morphological and angiarchitectural characteristics were proved to be related to hemorrhage of brain AVMs. The SM grading scale is used as the most common classification system in bAVMs, consisting of three anatomical factors (size of nidus, relative position of eloquent location, and patterns of draining veins) [38]. The five-classified grading system is a powerful tool for predicting operative risks based on the radiological data. In the current study, the maximum diameter of bAVMs was the independent predictor for rupture. In accordance with the present results, previous studies have illustrated that the incidence of subsequent hemorrhage increased with decreasing the size of lesions in untreated bAVMs [39, 40]. A small size of bAVMs (<3 cm) were more likely to present with bleeding compared to the larger lesions. In terms of other characteristics of bAVMs, no significant relationship between deep venous drainage or eloquent location and hemorrhage was evident in the present analyses. However, these variables were considered to be the key predictors for outcomes in previous studies [38]. The negative finding may be limited by the small sample size of enrolled participants.

There are several limitations to our study. First, this was a retrospective study with relatively small sample size, and it was difficult to avoid selection bias. Second, the diet patterns and supplements of folic acid or vitamins were not taken into consideration, and the variables may influence the metabolism of Hcy and affect the results. Third, there was a lack of data regarding levels of MMP-9 and hemodynamics parameters owing to the retrospective design; the direct relation between hemodynamic status and Hcy would be concluded with the support of evidence generated from TCD or DSA hemodynamic evaluation. Fourth, the clinical data derived from a high-volume single institution may present tentative associations between risk factors and bAVMs. Further prospective studies comparing Hcy before and after hemorrhage are required to investigate the predictive value for bAVM ruptures.

5. Conclusions
In conclusion, our results indicated that the Hcy levels were significantly associated with the risk of rupture in bAVM patients. A higher concentration of Hcy carried a lower prevalence of hemorrhage. It is recommended to monitor the factor in patients with bAVMs, which may facilitate the guidance of subsequent nutritional management strategies.

Data Availability
The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

Acknowledgments
This study was supported by the National Key Technologies Research and Development Program of China (2016YFC1301800), Beijing Science and Technology Supporting Plan (D161100003816005), and Beijing Municipal Administration of Hospitals’ Mission Plan (SML20150501).

References

[1] R. M. Friedlander, “Arteriovenous malformations of the brain,” The New England Journal of Medicine, vol. 356, no. 26, pp. 2704–2712, 2007.
[2] S. I. Nikolaev, S. Vetiska, X. Bonilla et al., “Somatic Activating KRAS Mutations in arteriovenous malformations of the brain,” The New England Journal of Medicine, vol. 378, no. 3, pp. 250–261, 2018.
[3] H. Kim, R. A.-S. Salman, C. E. McCulloch, C. Stapf, W. L. Young, and For the MARS Coinvestigators, “Untreated brain arteriovenous malformation: patient-level meta-analysis of hemorrhage predictors,” Neurology, vol. 83, no. 7, pp. 590–597, 2014.
[4] X. Lv and G. Wang, “Review of de novo cerebral arteriovenous malformation: haemorrhage risk, treatment approaches and outcomes,” The Neuroradiology Journal, vol. 31, no. 3, pp. 224–229, 2018.
[5] M. Holmes, P. Newcombe, J. Hubacek et al., “Effect modification by population dietary folate on the association between MTHFR genotype, homocysteine, and stroke risk: a meta-analysis of genetic studies and randomised trials,” The Lancet, vol. 378, no. 9791, pp. 584–594, 2011.
[6] C. Boushey, S. Beresford, G. Omenn, and A. Motulsky, “A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folate intake,” JAMA, vol. 274, no. 13, pp. 1049–1057, 1995.
[7] I. Wiernicki, B. Millo, K. Safranow, B. Gorecka-Szyld, and P. Gutowski, “MMP-9, homocysteine and CRP circulating levels are associated with intraluminal thrombus thickness of abdominal aortic aneurysms–new implication of the old
biomarkers,” Disease Markers, vol. 31, no. 2, Article ID 783721, pp. 67–74, 2011.

[8] M. T. Lawton, W. C. Rutledge, H. Kim et al., "Brain arteriovenous malformations,” Nature Reviews. Disease Primers, vol. 1, no. 1, p. 15008, 2015.

[9] Y. Liu, J.-H. Song, X.-H. Hou et al., “Elevated homocysteine as an independent risk for intracranial atherosclerotic stenosis,” Aging (Albany NY), vol. 11, no. 11, pp. 3824–3831, 2019.

[10] T. Li, B. Yu, Z. Liu et al., “Homocysteine directly interacts and activates the angiotensin II type 1 receptor to aggravate vascular injury,” Nature Communications, vol. 9, no. 1, p. 11, 2018.

[11] Y. Xu, Y. Tian, H. J. Wei, J. F. Dong, and J. N. Zhang, “A model of atherosclerotic cerebral aneurysms in rats,” Neuroscience Letters, vol. 494, no. 2, pp. 139–144, 2011.

[12] M. Korai, K. T. Kitazato, Y. Tada et al., “Hyperhomocysteinemia induced by excessive methionine intake promotes rupture of cerebral aneurysms in ovariectomized rats,” Journal of Neuroinflammation, vol. 13, no. 1, p. 165, 2016.

[13] K. J. Halazun, K. A. Bolfkin, S. Asthana, C. Evans, M. Henderson, and J. L. Spark, “Hyperhomocysteinemia is associated with the risk of abdominal aortic aneurysm expansion,” European Journal of Vascular and Endovascular Surgery, vol. 33, no. 4, pp. 391–394, 2007, discussion 395–396.

[14] F. Zhou, B. Chen, C. Chen et al., “Elevated homocysteine levels contribute to larger hematoma volume in patients with intracerebral hemorrhage,” Journal of Stroke and Cerebrovascular Diseases, vol. 24, no. 4, pp. 784–788, 2015.

[15] T. L. Sudath, D. K. Powell, C. D. Smith, A. Greenstein, and D. M. Wilcock, "Induction of hyperhomocysteinemia models vascular dementia by induction of cerebral microhemorrhages and neuroinflammation,” Journal of Cerebral Blood Flow & Metabolism, vol. 33, no. 5, pp. 708–715, 2013.

[16] A. W. McEvoy, C. Marras, N. D. Kitchen, and A. Briddon, “Plasma total homocysteine and subarachnoid haemorrhage in a co-factor replete population,” Amino Acids, vol. 21, no. 3, pp. 237–241, 2001.

[17] Z. Li, L. Sun, H. Zhang et al., "Elevated plasma homocysteine was associated with hemorrhagic and ischemic stroke, but methylenetetrahydrofolate reductase gene C677T polymorphism was a risk factor for thrombotic stroke: a multicenter case-control study in China," Stroke, vol. 34, no. 9, pp. 2085–2090, 2003.

[18] H. Iso, Y. Moriyama, S. Sato et al., "Serum total homocysteine concentrations and risk of stroke and its subtypes in Japanese," Circulation, vol. 109, no. 22, pp. 2766–2772, 2004.

[19] Z. Zhou, Y. Liang, H. Qu et al., “Plasma homocysteine concentrations and risk of intracerebral hemorrhage: a systematic review and meta-analysis,” Scientific Reports, vol. 8, no. 1, p. 2568, 2018.

[20] T. H. T. Chiu, H.-R. Chang, L.-Y. Wang, C.-C. Chang, M.-N. Lin, and C.-L. Lin, "Vegetarian diet and incidence of total, ischemic, and hemorrhagic stroke in 2 cohorts in Taiwan," Neurology, vol. 94, no. 11, pp. e1112–e1121, 2020.

[21] Y. He, Y. Li, Y. Chen, L. Feng, and Z. Nie, "Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 24, no. 11, pp. 1158–1165, 2014.

[22] B. Van Guelpen, J. Hultdin, I. Johansson et al., "Folate, vitamin B12, and risk of ischemic and hemorrhagic stroke: a prospective, nested case-referent study of plasma concentrations and dietary intake," Stroke, vol. 36, no. 7, pp. 1426–1431, 2005.

[23] C. S. Ogilvy, P. E. Stieg, I. Awad et al., "Recommendations for the management of intracranial arteriovenous malformations: a statement for healthcare professionals from a special writing group of the stroke council, American Stroke Association," Circulation, vol. 103, no. 21, pp. 2644–2657, 2001.

[24] S.-B. Jeon, D.-W. Kang, J. S. Kim, and S. U. Kwon, "Homocysteine, small-vessel disease, and atherosclerosis: an MRI study of 825 stroke patients," Neurology, vol. 83, no. 8, pp. 695–701, 2014.

[25] Q. Wang, J. Zhang, K. Zhao, and B. Xu, "Hyperhomocysteinemia is an independent risk factor for intracranial aneurysms: a case-control study in a Chinese Han population,” Neurosurgical Review, vol. 43, no. 4, pp. 1127–1134, 2020.

[26] M. Kumar, S. Goudihalli, K. Mukherjee, S. Dhandapani, and R. Sandhir, "Methylenetetrahydrofolate reductase C677T variant and hyperhomocysteinemia in subarachnoid hemorrhage patients from India,” Metabolic Brain Disease, vol. 33, no. 5, pp. 1617–1624, 2018.

[27] S. Dhandapani, S. Goudihalli, K. K. Mukherjee et al., "Prospective study of the correlation between admission plasma homocysteine levels and neurological outcome following subarachnoid hemorrhage: a case for the reverse epidemiology paradox?,” Acta Neurochirurgica, vol. 157, no. 3, pp. 399–407, 2015.

[28] Y. Suo, W. Chen, Y. Pan et al., "Magnetic resonance imaging markers of cerebral small vessel disease in hematoma expansion of intracerebral hemorrhage," Journal of Stroke and Cerebrovascular Diseases, vol. 27, no. 7, pp. 2006–2013, 2018.

[29] D. Lominadze, A. M. Roberts, N. Tyagi, K. S. Moshal, and S. C. Tyagi, "Homocysteine causes cerebrovascular leakage in mice,” American Journal of Physiology. Heart and Circulatory Physiology, vol. 290, no. 3, pp. H1206–H1213, 2006.

[30] N. Tyagi, W. Gillespie, J. C. Vacek, U. Sen, S. C. Tyagi, and D. Lominadze, “Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway,” Journal of Cellular Physiology, vol. 220, no. 1, pp. 257–266, 2009.

[31] H. Min, J. Hong, I.-H. Cho et al., "TLR2-induced astrocyte MMP9 activation compromises the blood brain barrier and exacerbates intracerebral hemorrhage in animal models,” Molecular Brain, vol. 8, no. 1, p. 23, 2015.

[32] T. Hashimoto, G. Wen, M. T. Lawton et al., "Abnormal expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in brain arteriovenous malformations,” Stroke, vol. 34, no. 4, pp. 925–931, 2003.

[33] A. Riza Erbay, H. Turhan, A. S. Yasar et al., "Elevated level of plasma homocysteine in patients with slow coronary flow,” International Journal of Cardiology, vol. 102, no. 3, pp. 419–423, 2005.

[34] K. Yamashita, H. Tasaki, Y. Nagai et al., "Experimental hyperhomocysteinemia impairs coronary flow velocity reserve,” International Journal of Cardiology, vol. 104, no. 2, pp. 163–169, 2005.

[35] H. Tanriverdi, H. Evrengul, S. Tanriverdi et al., "Carotid intima-media thickness in coronary slow flow: relationship with plasma homocysteine levels,” Coronary Artery Disease, vol. 17, no. 4, pp. 331–337, 2006.

[36] M. H. Lim, Y. I. Cho, and S. K. Jeong, "Homocysteine and pulsatility index of cerebral arteries,” Stroke, vol. 40, no. 10, pp. 3216–3220, 2009.

[37] Y. Sun, C.-J. Lu, R.-C. Chen, and K.-L. Chien, "Lack of association between total serum homocysteine and extracranial
cerebral flow,” *Journal of the Formosan Medical Association*, vol. 109, no. 4, pp. 278–286, 2010.

[38] R. F. Spetzler and N. A. Martin, “A proposed grading system for arteriovenous malformations,” *Journal of Neurosurgery*, vol. 65, no. 4, pp. 476–483, 1986.

[39] R. F. Spetzler, R. W. Hargaves, P. W. McCormick, J. M. Zabramski, R. A. Flom, and R. S. Zimmerman, “Relationship of perfusion pressure and size to risk of hemorrhage from arteriovenous malformations,” *Journal of Neurosurgery*, vol. 76, no. 6, pp. 918–923, 1992.

[40] M. Reitz, N. von Spreckelsen, E. Vettorazzi et al., “Angioarchitectural risk factors for hemorrhage and clinical long-term outcome in pediatric patients with cerebral arteriovenous malformations,” *World Neurosurgery*, vol. 89, pp. 540–551, 2016.